• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cardiovascular

Amgen wins marketing authorization for Repatha single-dose delivery option

February 23, 2017 By Sarah Faulkner

Amgen

Amgen (NSDQ:AMGN) said today that the European Commission granted a change to the marketing authorization of its Repatha device, approving a single-dose delivery option. The pre-filled cartridge mini-doser is a hands-free device that is designed to provide 420 mg of Repatha (evolocumab) in a single injection for patients with cardiovascular disease. The company touted its […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen

Amgen tops Q4 earnings, touts Repatha cardiovascular outcomes

February 3, 2017 By Sarah Faulkner

Amgen

Shares in Amgen (NSDQ:AMGN) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results and touted data from a trial for its cholesterol drug, Repatha. The Thousand Oaks, Calif.-based company posted profits of $1.94 billion, or $2.59 per share, on sales of $5.97 billion for the 3 months ended Dec. 31, for bottom-line […]

Filed Under: Cardiovascular, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Amgen

J&J, Actelion still in talks despite Opsumit failure

January 23, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Mergers & Acquisitions, Respiratory Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

BioCardia launches pivotal trial for CardiAmp heart failure treatment

December 30, 2016 By Sarah Faulkner

BioCardia (NSDQ:BCDA) initiated its CardiAmp pivotal trial this week to evaluate its cell therapy at 40 clinical sites across the U.S. The pivotal trial is a part of the company’s efforts for premarket approval, as regulated by the FDA’s Center for Biologics Evaluation and Research division. “We are honored to be working with the leading […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stem Cells, Vascular Tagged With: BioCardia

Bayer, Versant close $225m Series A to launch stem cell company

December 12, 2016 By Sarah Faulkner

Bayer, Versant close $225m Series A to launch stem cell company

Bayer (ETR:BAYN) and Versant Ventures said today that the 2 groups closed a $225 million Series A financing round to launch BlueRock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies. The funds are estimated to support the company for 4 years as it advances cell therapy clinical programs for cardiovascular and degenerative diseases. “Accessing […]

Filed Under: Cardiovascular, Discovery, Featured, Funding Roundup, Neurological, Stem Cells, Wall Street Beat Tagged With: Bayer AG, Versant Ventures

AngioSoma taps new CEO

December 9, 2016 By Sarah Faulkner

AngioSoma taps new CEO

AngioSoma (OTCQB:SOAN) said today that it named Ken Stephenson to the Montgomery, Texas-based company’s corner office. Alexanderia Blankenship will now serve as chief operating officer and executive VP. Stephenson has worked with hospitals, health insurance organizations and physician’s offices throughout Texas, according to the company. He previously helped set up practices for interventional radiologists and […]

Filed Under: Cardiovascular, Clinical Trials, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AngioSoma

Micell begins MiStent clinical trial in Japan

November 29, 2016 By Sarah Faulkner

Micell begins MiStent clinical trial in Japan

Micell Technologies said today that it began its Dessolve J randomized, double-blind study comparing its MiStent SES sirolimus eluting absorbable polymer coronary stent to the Xience V everolimus eluting coronary stent in patients with coronary artery disease. The Durham, N.C.-based company touts its device as a bare-metal stent coated in crystalline drug, sirolimus, and an absorbable polymer, […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured Tagged With: Micell Technologies

OrbusNeich launches Combo Plus stent

November 21, 2016 By Sarah Faulkner

OrbusNeich

OrbusNeich said today that it launched the latest version of its dual-therapy stent, the Combo Plus, featuring an antibody biological coating designed to promote vessel healing in patients with complex coronary artery disease. After the stent is implanted, the biological coating captures endothelial progenitor cells and kicks off formation of an endothelial layer. A coating of bioabsorbable polymer […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Vascular Tagged With: OrbusNeich

Injectable Regeneron biologic therapy reduces triglycerides, cholesterol

November 15, 2016 By Sarah Faulkner

Regeneron

Researchers from the University of Pennsylvania presented preliminary data from a trial evaluating Regeneron Pharmaceutical‘s (NSDQ:REGN) injectable biologic drug therapy for reducing triglyceride levels. The team, led by Dr. Richard Dunbar, presented their work at the annual meeting of the American Heart Assn. The Phase I, placebo-controlled, double-blind study tested the safety and efficacy of Evinacumab, an […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Research & Development Tagged With: Regeneron

Mast Therapeutics touts interim data from pulmonary hypertension study

November 4, 2016 By Sarah Faulkner

Mast Therapeutics subsidiary launches trial for inhaled sodium nitrite solution

Mast Therapeutics (NYSE:MSTX) touted interim data from a Phase II study of its AIR001 candidate in patients with pulmonary hypertension (PH) and PH associated with heart failure with preserved ejection fraction. Positive interim results from the ongoing trial were published in the Journal of Clinical Investigation. The San Diego-based company enrolled 50 patients to study its nebulized […]

Filed Under: Cardiovascular, Clinical Trials, Featured Tagged With: Mast Therapeutics

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 10
  • Go to page 11
  • Go to page 12
  • Go to page 13
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS